Description: Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. It develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Home Page: www.bio-heart.com
Building 4
Shanghai,
China
Phone:
86 21 6879 8511
Officers
| Name | Title |
|---|---|
| Mr. Li Wang | Executive Chairman of the Board, CEO & GM |
| Mr. Yunqing Wang | CFO, Joint Company Secretary & Executive Director |
| Ms. Peili Wang | Financial Manager & Executive Director |
| Dr. Bradley Stewart Hubbard D.V.M., DVM | Chief Medical Officer |
| Ms. Siu Ying Kwok | Joint Company Secretary |
| Mr. Tao Cai | Chairperson of the Board of Supervisors & Head of Technology of BRS |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5215 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 54 |